DK1656391T3 - Modificerede humane IGF-1R antistoffer - Google Patents

Modificerede humane IGF-1R antistoffer

Info

Publication number: DK1656391T3
Authority: DK; Denmark
Prior art keywords: antibodies; modified human; human igf; igf; modified
Prior art date: 2003-08-13

Application number

DK04744197.7T

Other languages

English (en)

Inventor

Bruce David Cohen

Vahe Bedian

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-13

Filing date

2004-08-03

Publication date

2011-01-03

2004-08-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2011-01-03 Application granted granted Critical

2011-01-03 Publication of DK1656391T3 publication Critical patent/DK1656391T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK04744197.7T 2003-08-13 2004-08-03 Modificerede humane IGF-1R antistoffer DK1656391T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49520003P	2003-08-13	2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en)	2003-08-13	2004-08-03	Modified human igf-1r antibodies

Publications (1)

Publication Number	Publication Date
DK1656391T3 true DK1656391T3 (da)	2011-01-03

Family

ID=34193291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04744197.7T DK1656391T3 (da)	2003-08-13	2004-08-03	Modificerede humane IGF-1R antistoffer

Country Status (37)

Country	Link
US (2)	US7371378B2 (da)
EP (1)	EP1656391B1 (da)
JP (1)	JP4638870B2 (da)
KR (1)	KR100825156B1 (da)
CN (1)	CN1835975B (da)
AP (1)	AP2006003510A0 (da)
AR (1)	AR045247A1 (da)
AT (1)	ATE484525T1 (da)
AU (1)	AU2004265152A1 (da)
BR (1)	BRPI0413466A (da)
CA (1)	CA2535071A1 (da)
CL (1)	CL2004002035A1 (da)
CR (1)	CR8233A (da)
DE (1)	DE602004029581D1 (da)
DK (1)	DK1656391T3 (da)
EA (1)	EA200600234A1 (da)
EC (1)	ECSP066359A (da)
ES (1)	ES2351395T3 (da)
GT (1)	GT200400158A (da)
IL (1)	IL173273A (da)
IS (1)	IS8266A (da)
MA (1)	MA27988A1 (da)
MX (1)	MXPA06001634A (da)
NL (1)	NL1026829C2 (da)
NO (1)	NO20060542L (da)
OA (1)	OA13234A (da)
PA (1)	PA8608801A1 (da)
PE (1)	PE20050339A1 (da)
PL (1)	PL1656391T3 (da)
PT (1)	PT1656391E (da)
RS (1)	RS20060099A (da)
TN (1)	TNSN06050A1 (da)
TW (1)	TWI294915B (da)
UA (1)	UA85058C2 (da)
UY (1)	UY28464A1 (da)
WO (1)	WO2005016967A2 (da)
ZA (1)	ZA200601231B (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME00502B (me)	2001-01-05	2011-10-10	Amgen Fremont Inc	Antitjela za insulinu sličan receptor faktora i rasta
EP1506286B1 (en)	2002-05-24	2014-03-19	Merck Sharp & Dohme Corp.	Neutralizing human anti-igfr antibody
CA2524305C (en) *	2003-05-01	2015-12-08	Imclone Systems Incorporated	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DE602004029581D1 (de) *	2003-08-13	2010-11-25	Pfizer Prod Inc	Modifizierte humane igf-1r antikörper
US7326567B2 (en)	2003-11-12	2008-02-05	Schering Corporation	Plasmid system for multigene expression
TW200526684A (en)	2003-11-21	2005-08-16	Schering Corp	Anti-IGFR1 antibody therapeutic combinations
KR20080019733A (ko)	2004-07-16	2008-03-04	화이자 프로덕츠 인코포레이티드	항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
FR2873699B1 (fr) *	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
PT1828249E (pt)	2004-12-03	2011-02-25	Schering Corp	Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) *	2005-01-10	2005-02-16	Cambridge Antibody Tech	Method of mutagenesis
JP4875064B2 (ja) *	2005-04-15	2012-02-15	シェーリングコーポレイション	癌を処置または予防するための方法および組成物
NZ564098A (en) *	2005-06-15	2010-04-30	Schering Corp	Anti-IGF1R antibody formulations
CA2612449A1 (en) *	2005-06-17	2006-12-28	Imclone Systems Incorporated	Receptor antagonists for treatment of metastatic bone cancer
FR2888850B1 (fr) *	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
AP2008004569A0 (en) *	2006-02-03	2008-08-31	Imclone Systems Inc	IGR-IR antagonists as adjuvants for treatment of prostrate cancer
JP2009531371A (ja) *	2006-03-28	2009-09-03	エフ．ホフマン−ラロシュアーゲー	抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
NZ573187A (en) *	2006-06-02	2011-11-25	Pfizer Prod Inc	Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
AR064464A1 (es) *	2006-12-22	2009-04-01	Genentech Inc	Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
AU2012203443B2 (en) *	2007-03-02	2014-03-06	Amgen Inc.	Methods and compositions for treating tumor diseases
AU2008223541B2 (en) *	2007-03-02	2012-04-05	Amgen Inc.	Methods and compositions for treating tumor diseases
EP2136839A4 (en) *	2007-03-22	2010-04-07	Imclone Llc	STABLE ANTIBODY FORMULATIONS
EP2559771A3 (en)	2007-05-17	2013-06-12	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
ES2388017T3 (es)	2007-12-21	2012-10-05	Roche Glycart Ag	Ensayo de estabilidad de anticuerpos
US20110104256A1 (en) *	2008-03-25	2011-05-05	Yaolin Wang	Methods for treating or preventing colorectal cancer
US20110129456A1 (en) *	2008-05-05	2011-06-02	Yaolin Wang	Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
EP2356154A4 (en) *	2008-11-06	2012-12-19	Alexion Pharma Inc	DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
EP2236139A1 (en)	2009-03-31	2010-10-06	F. Hoffmann-La Roche AG	Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100316639A1 (en)	2009-06-16	2010-12-16	Genentech, Inc.	Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
SI2493922T1 (sl)	2009-10-26	2017-06-30	F. Hoffmann-La Roche Ag	Postopek za proizvodnjo glikoziliranega imunoglobulina
EP2494070A2 (en)	2009-10-30	2012-09-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
KR101721187B1 (ko) *	2009-12-23	2017-03-29	에스바테크 - 어 노바티스 컴파니 엘엘씨	면역원성의 감소 방법
WO2011101328A2 (en)	2010-02-18	2011-08-25	Roche Glycart Ag	Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
RU2012157167A (ru)	2010-07-12	2014-08-20	КовЭкс Текнолоджиз Айэлэнд Лимитед	Полифункциональные антительные конъюгаты
MX2013008833A (es)	2011-02-02	2013-12-06	Amgen Inc	Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
DK2699598T3 (da)	2011-04-19	2019-04-23	Pfizer	Kombinationer af anti-4-1bb-antistoffer og adcc-inducerende antistoffer til behandling af kræft
EP2766497A1 (en)	2011-10-13	2014-08-20	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP3447071A1 (en) *	2012-01-09	2019-02-27	Pfizer Healthcare Ireland	Mutant antibodies and conjugation thereof
EP2631653A1 (en)	2012-02-24	2013-08-28	Charité - Universitätsmedizin Berlin	Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
BR112015010240A2 (pt) *	2012-11-06	2017-08-22	Medimmune Ltd	Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
WO2014177459A2 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (uk)	2013-04-29	2018-11-12	Ф. Хоффманн-Ля Рош Аг	Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CN103319598B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	抗胰岛素样生长因子-1受体抗体及其编码基因和应用
MX380658B (es)	2014-01-15	2025-03-11	Hoffmann La Roche	Variantes de region fc con union mejorada de la proteina a.
BR112019013953A2 (pt)	2017-01-06	2020-02-11	Abl Bio Inc.	Anticorpo anti-a-syn e uso do mesmo
IL272227B2 (en) *	2017-07-27	2025-09-01	iTeos Belgium SA	Anti-tigit antibodies
EP3725806A4 (en)	2017-12-14	2022-03-30	ABL Bio Inc.	BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1996033735A1 (en)	1995-04-27	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6657103B1 (en) *	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es)	1995-04-20	2001-05-16	Pfizer	Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
IL118626A0 (en) *	1996-06-11	1996-10-16	Xtl Biopharmaceuticals Limited	Anti HBV antibody
KR20000067904A (ko)	1996-07-18	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko)	1996-08-23	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐아미노 하이드록삼산 유도체
KR20010071271A (ko)	1998-05-15	2001-07-28	존 비. 랜디스	방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
US6682736B1 (en) *	1998-12-23	2004-01-27	Abgenix, Inc.	Human monoclonal antibodies to CTLA-4
HUP0200575A3 (en)	1999-03-25	2004-11-29	Abbott Gmbh & Co Kg	Human antibodies that bind human il-12 and methods for producing
ES1042735Y (es)	1999-04-07	2000-02-16	Martinez Fernando Martinez	Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en)	2000-06-13	2003-09-04	City Of Hope	Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de)	2000-07-12	2003-07-31	Karlsruhe Forschzent	HTS-Kryomagnet und Aufmagnetisierungsverfahren
ME00502B (me) *	2001-01-05	2011-10-10	Amgen Fremont Inc	Antitjela za insulinu sličan receptor faktora i rasta
US7132511B2 (en)	2001-02-19	2006-11-07	Merck Patent Gmbh	Modified anti-EGFR antibodies with reduced immunogenicity
SI1461359T1 (sl)	2002-01-18	2007-06-30	Pf Medicament	Nova anti IGF-IR protitelesa in njihova uporaba
AU2003231554A1 (en)	2002-04-30	2003-11-17	Kyowa Hakko Kogyo Co., Ltd.	Antibody to human insulin-like growth factor
EP1506286B1 (en)	2002-05-24	2014-03-19	Merck Sharp & Dohme Corp.	Neutralizing human anti-igfr antibody
GB0212303D0 (en)	2002-05-28	2002-07-10	Isis Innovation	Molecular targetting of IGF-1 receptor
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
PL378812A1 (pl)	2003-02-13	2006-05-29	Pfizer Products Inc.	Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
JP2007528201A (ja)	2003-03-14	2007-10-11	ファルマシア・コーポレーション	癌治療のためのｉｇｆ−ｉ受容体に対する抗体
ES2383014T3 (es)	2003-04-02	2012-06-15	F. Hoffmann-La Roche Ag	Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
DE602004029581D1 (de) *	2003-08-13	2010-11-25	Pfizer Prod Inc	Modifizierte humane igf-1r antikörper

2004
- 2004-08-03 DE DE602004029581T patent/DE602004029581D1/de not_active Expired - Lifetime
- 2004-08-03 UA UAA200601349A patent/UA85058C2/ru unknown
- 2004-08-03 BR BRPI0413466-4A patent/BRPI0413466A/pt not_active IP Right Cessation
- 2004-08-03 PT PT04744197T patent/PT1656391E/pt unknown
- 2004-08-03 RS YUP-2006/0099A patent/RS20060099A/sr unknown
- 2004-08-03 AU AU2004265152A patent/AU2004265152A1/en not_active Abandoned
- 2004-08-03 AT AT04744197T patent/ATE484525T1/de active
- 2004-08-03 PL PL04744197T patent/PL1656391T3/pl unknown
- 2004-08-03 EP EP04744197A patent/EP1656391B1/en not_active Expired - Lifetime
- 2004-08-03 AP AP2006003510A patent/AP2006003510A0/xx unknown
- 2004-08-03 CA CA002535071A patent/CA2535071A1/en not_active Abandoned
- 2004-08-03 MX MXPA06001634A patent/MXPA06001634A/es unknown
- 2004-08-03 DK DK04744197.7T patent/DK1656391T3/da active
- 2004-08-03 OA OA1200600046A patent/OA13234A/en unknown
- 2004-08-03 CN CN2004800230991A patent/CN1835975B/zh not_active Expired - Fee Related
- 2004-08-03 JP JP2006523070A patent/JP4638870B2/ja not_active Expired - Fee Related
- 2004-08-03 WO PCT/IB2004/002555 patent/WO2005016967A2/en not_active Ceased
- 2004-08-03 KR KR1020067002957A patent/KR100825156B1/ko not_active Expired - Fee Related
- 2004-08-03 ES ES04744197T patent/ES2351395T3/es not_active Expired - Lifetime
- 2004-08-03 EA EA200600234A patent/EA200600234A1/ru unknown
- 2004-08-09 PE PE2004000773A patent/PE20050339A1/es not_active Application Discontinuation
- 2004-08-10 CL CL200402035A patent/CL2004002035A1/es unknown
- 2004-08-11 UY UY28464A patent/UY28464A1/es not_active Application Discontinuation
- 2004-08-11 AR ARP040102870A patent/AR045247A1/es active IP Right Grant
- 2004-08-12 GT GT200400158A patent/GT200400158A/es unknown
- 2004-08-12 US US10/917,073 patent/US7371378B2/en not_active Expired - Fee Related
- 2004-08-12 PA PA20048608801A patent/PA8608801A1/es unknown
- 2004-08-12 TW TW093124269A patent/TWI294915B/zh not_active IP Right Cessation
- 2004-08-12 NL NL1026829A patent/NL1026829C2/nl not_active IP Right Cessation
2006
- 2006-01-19 IL IL173273A patent/IL173273A/en not_active IP Right Cessation
- 2006-01-26 IS IS8266A patent/IS8266A/is unknown
- 2006-02-02 NO NO20060542A patent/NO20060542L/no not_active Application Discontinuation
- 2006-02-10 EC EC2006006359A patent/ECSP066359A/es unknown
- 2006-02-10 ZA ZA200601231A patent/ZA200601231B/en unknown
- 2006-02-13 TN TNP2006000050A patent/TNSN06050A1/fr unknown
- 2006-02-13 MA MA28790A patent/MA27988A1/fr unknown
- 2006-02-13 CR CR8233A patent/CR8233A/es not_active Application Discontinuation
2008
- 2008-03-03 US US12/041,341 patent/US7575746B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20060035796A (ko)	2006-04-26
DE602004029581D1 (de)	2010-11-25
US20050069539A1 (en)	2005-03-31
US7371378B2 (en)	2008-05-13
ZA200601231B (en)	2007-05-30
CN1835975B (zh)	2012-11-21
MXPA06001634A (es)	2006-04-28
ES2351395T3 (es)	2011-02-04
IL173273A0 (en)	2006-06-11
TW200516145A (en)	2005-05-16
GT200400158A (es)	2005-07-22
TWI294915B (en)	2008-03-21
US20080181891A1 (en)	2008-07-31
JP2007527705A (ja)	2007-10-04
PA8608801A1 (es)	2005-03-03
UA85058C2 (ru)	2008-12-25
CN1835975A (zh)	2006-09-20
CA2535071A1 (en)	2005-02-24
JP4638870B2 (ja)	2011-02-23
ECSP066359A (es)	2006-10-31
PE20050339A1 (es)	2005-05-17
IL173273A (en)	2011-10-31
AR045247A1 (es)	2005-10-19
IS8266A (is)	2006-01-26
KR100825156B1 (ko)	2008-04-24
EA200600234A1 (ru)	2006-08-25
BRPI0413466A (pt)	2006-10-17
NL1026829C2 (nl)	2005-07-05
UY28464A1 (es)	2005-03-31
CR8233A (es)	2007-01-18
EP1656391A2 (en)	2006-05-17
CL2004002035A1 (es)	2005-06-03
PT1656391E (pt)	2010-12-06
PL1656391T3 (pl)	2011-03-31
WO2005016967A2 (en)	2005-02-24
EP1656391B1 (en)	2010-10-13
AP2006003510A0 (en)	2006-02-28
WO2005016967A3 (en)	2005-04-14
TNSN06050A1 (fr)	2007-10-03
OA13234A (en)	2006-12-13
ATE484525T1 (de)	2010-10-15
AU2004265152A1 (en)	2005-02-24
MA27988A1 (fr)	2006-07-03
NL1026829A1 (nl)	2005-02-15
US7575746B2 (en)	2009-08-18
NO20060542L (no)	2006-05-03
RS20060099A (sr)	2008-08-07

Publication	Publication Date	Title
ATE484525T1 (de)	2010-10-15	Modifizierte humane igf-1r antikörper
DK1844074T3 (da)	2013-07-15	Humane antistoffer og proteiner
DK1599504T3 (da)	2015-03-09	Modificeret antistof
DE602004026768D1 (de)	2010-06-02	Therapeutische anti-igfr1-antikörper-kombinationen
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
DK1432735T3 (da)	2012-08-06	Antagonistiske humane anti-htnfsf13b-antistoffer
IL258718A (en)	2018-06-28	Human anti-il-23 antibodies,compositions, methods and uses
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODY
NO20052889D0 (no)	2005-06-14	Humane monoklonale antistoffer mot CD25
ATE440867T1 (de)	2009-09-15	Interleukin-10-antikírper
CY2016016I2 (el)	2016-12-14	Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
CY2016035I2 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
PL2177537T3 (pl)	2012-06-29	Przeciwciała przeciw MadCAM
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
HUE053833T2 (hu)	2021-07-28	Bispecifikus ellenanyag funkcionális proteinek helyettesítésére
IS3021B (is)	2020-04-15	Mótefni gegn M-CSF
ATE396612T1 (de)	2008-06-15	Schleppnetz
CY2012019I1 (el)	2015-08-05	Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK1817343T3 (da)	2014-09-15	Humane monoklone antistoffer mod humant IL-4
EP1598368A4 (en)	2007-07-25	ANTI-PCI neutralizing ANTIBODY
DK1809660T3 (da)	2014-10-20	Thymus-specifikt protein
EP1826218A4 (en)	2009-11-25	ANTI-HUMAN BAFF ANTIBODIES
DE60336777D1 (de)	2011-05-26	Responder
EP1646401A4 (en)	2007-07-18	SPECIFIC HUMAN ANTIBODIES
EP1671557A4 (en)	2015-01-07	DISPOSABLE WIG